Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADT + docetaxel + darolutamide triple therapy for metastatic prostate cancer (YHCG-006)
ChiCTR2600118253Phase 4Not yet recruiting
- Sponsor
- First Affiliated Hospital of Ningbo University
- Start
- Feb 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of darolutamide in prostate cancer (PCa), sponsored by First Affiliated Hospital of Ningbo University. Primary endpoints: PSA response rate, Proportion of PSA < 0.2 ng/mL and 1 more. Planned start Feb 2026; status: not yet recruiting.
02
Drugs
darolutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on ChiCTR2600118253.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600118253.